Evidence map›Paper›PMID 29872440›Full record

ArticleFrontiers in immunology2018

Tannic Acid-Modified Silver and Gold Nanoparticles as Novel Stimulators of Dendritic Cells Activation.

Piotr Orlowski, Emilia Tomaszewska, Katarzyna Ranoszek-Soliwoda, Marianna Gniadek, Olga Labedz, Tadeusz Malewski, Julita Nowakowska, Grzegorz Chodaczek, Grzegorz Celichowski, Jaroslaw Grobelny and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Design andMaterials today. Bio · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Cancer Therapy by Silver Nanoparticles: Fiction or Reality?International journal of molecular sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Piotr OrlowskiMilitary Institute of Hygiene and Epidemiology, Warsaw, Poland.
Emilia TomaszewskaDepartment of Materials Technology and Chemistry, Faculty of Chemistry, University of Lodz, Lodz, Poland.
Katarzyna Ranoszek-SoliwodaDepartment of Materials Technology and Chemistry, Faculty of Chemistry, University of Lodz, Lodz, Poland.
Marianna GniadekFaculty of Chemistry, University of Warsaw, Warsaw, Poland.
Olga LabedzFaculty of Chemistry, University of Warsaw, Warsaw, Poland.
Tadeusz MalewskiMuseum and Institute of Zoology, Polish Academy of Science, Warsaw, Poland.
Julita NowakowskaLaboratory of Electron and Confocal Microscopy, Faculty of Biology, University of Warsaw, Warsaw, Poland.
Grzegorz ChodaczekWroclaw Research Centrum EIT+, Wroclaw, Poland.
Grzegorz CelichowskiDepartment of Materials Technology and Chemistry, Faculty of Chemistry, University of Lodz, Lodz, Poland.
Jaroslaw GrobelnyDepartment of Materials Technology and Chemistry, Faculty of Chemistry, University of Lodz, Lodz, Poland.
Malgorzata KrzyzowskaMilitary Institute of Hygiene and Epidemiology, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silver nanoparticles (AgNPs) are promising new antimicrobial agents against a wide range of skin and mucosal pathogens. However, their interaction with the immune system is currently not fully understood. Dendritic cells (DCs) are crucial during development of T cell-specific responses against bacterial and viral pathogens. We have previously shown that tannic acid-modified silver nanoparticles (TA-AgNPs) consist of a promising microbicide against HSV-2. The aim of this study was to compare the ability of TA-AgNPs or TA-AuNPs of similar sizes (TA-Ag/AuNPs) to induce DCs maturation and activation in the presence of HSV-2 antigens when used at non-toxic doses. First, we used JAWS II DC line to test toxicity, ultrastructure as well as activation markers (MHC I and II, CD40, CD80, CD86, PD-L1) and cytokine production in the presence of TA-Ag/AuNPs. Preparations of HSV-2 treated with nanoparticles (TA-Ag/AuNPs-HSV-2) were further used to investigate HSV-2 antigen uptake, activation markers, TLR9 expression, and cytokine production. Additionally, we accessed proliferation and activation of HSV-2-specific T cells by DCs treated with TA-AgNP/AuNPs-HSV-2. We found that both TA-AgNPs and TA-AuNPs were efficiently internalized by DCs and induced activated ultrastructure. Although TA-AgNPs were more toxic than TA-AuNPs in corresponding sizes, they were also more potent stimulators of DCs maturation and TLR9 expression. TA-Ag/AuNPs-HSV-2 helped to overcome inhibition of DCs maturation by live or inactivated virus through up-regulation of MHC II and CD86 and down-regulation of CD80 expression. Down-regulation of CD40 expression in HSV-2-infected DCs was reversed when HSV-2 was treated with TA-NPs sized >30 nm. On the other hand, small-sized TA-AgNPs helped to better internalize HSV-2 antigens. HSV-2 treated with both types of NPs stimulated activation of JAWS II and memory CD8+ T cells, while TA-AgNPs treatment induced IFN-γ producing CD4+ and CD8+ T cells. Our study shows that TA-AgNPs or TA-AuNPs are good activators of DCs, albeit their final effect upon maturation and activation may be metal and size dependent. We conclude that TA-Ag/AuNPs consist of a novel class of nano-adjuvants, which can help to overcome virus-induced suppression of DCs activation.

Indexed as

GoldMetal NanoparticlesSilverTanninsAnimalsBiomarkersCell LineChlorocebus aethiopsCytokinesDendritic CellsGene ExpressionHerpesvirus 2, HumanImmunophenotypingLymphocyte ActivationMiceT-LymphocytesBiomarkersCytokinesGoldSilverTanninsdendritic cellsgold nanoparticlesHSV-2silver nanoparticlestannic acid

Identifiers

PMID29872440
PMCPMC5972285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.